Overview

A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer

Status:
Active, not recruiting

Trial end date:
2023-02-28

Target enrollment:

Participant gender:

Summary

An open-label, single-arm, phase II, multicentre clinical trial to determine the rate of durable clinical benefit of nivolumab in patients with class II expressing microsatellite stable colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

University of Birmingham

Collaborator:

Bristol-Myers Squibb

Treatments:

Nivolumab